Can Personalized Neoantigens Raise the T Cell Bar?

Research output: Contribution to journalComment/debatepeer-review


Ott et al. report the results of a phase 1B study in which a personalized neoantigen vaccine was combined with programmed death receptor-1 blockade in patients with advanced cancers. The study provides a framework for combinatorial vaccine therapies that could mount robust T cell responses, enhance tumor killing, and provide clinical benefit.

Original languageEnglish (US)
Pages (from-to)301-302
Number of pages2
Issue number2
StatePublished - Oct 15 2020

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)


Dive into the research topics of 'Can Personalized Neoantigens Raise the T Cell Bar?'. Together they form a unique fingerprint.

Cite this